Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• New use for an old drug: The potential of colchicine in CVD Darlene Dobkowski, MA; Regina Schaffer
• 2019: To close out a decade of progress, new ways of thinking about cardiology emerge Carl J. Pepine, MD, MACC
• Differences in dyslipidemia guidelines underscore complexity of CVD prevention Seth S. Martin, MD, MHS, FACC, FAHA, FASPC; Marc Engels, MD, PhD; Ethan Tumarkin, MD, PhD; Rhanderson Cardoso, MD
• Key opinion leaders discuss top news from 2019
• FDA approves CV event risk reduction indication for icosapent ethyl
• FDA panel does not recommend approval of vernakalant for AF
• 1.5 million US patients miss doses of ASCVD medication due to cost
• Medications that worsen HF often initiated, continued after hospitalization
• Early menopause raises risk for CVD
• ED visits spike, prescribing patterns change in wake of valsartan recall
• Twice-yearly inclisiran reduces LDL in ASCVD, FH
• TWILIGHT-ACS: Ticagrelor monotherapy beneficial in PCI for ACS
• A look at the interaction between opioids and oral P2Y12 inhibitors Dylan S. Wilson, PharmD, BCPS; Kathryn O. Jones, PharmD, BCPS; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
• CLOSE TO CURE
• COACT
• COSMIC-HF
• FRANCE-TAVI
• MEMS-HF
• PIONEER-OLE
• RECOVERY
• WRAP-IT